Revvity Inc. (NYSE:RVTY) Shares to Pay Quarterly Dividend of $0.07

Revvity Inc. (NYSE:RVTY) announced a quarterly dividend on Friday, July 31st. Shareholders of record on Friday, October 23rd will be given a dividend of $0.07 per share on Friday, November 13th. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd.

Revvity has a dividend payout ratio of 5.1% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Revvity to earn $5.92 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 4.7%.

Revvity Stock Performance

RVTY opened at $158.86 on Wednesday. The business has a 50 day moving average price of $137.99 and a two-hundred day moving average price of $114.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The company has a market capitalization of $17.73 billion, a price-to-earnings ratio of 74.79, a price-to-earnings-growth ratio of 2.75 and a beta of 1.06. Revvity has a 1-year low of $81.22 and a 1-year high of $166.25.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The company had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Revvity will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Revvity news, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the transaction, the insider owned 14,781 shares in the company, valued at approximately $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of Revvity stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,045 shares of company stock valued at $1,281,439 over the last 90 days. 0.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Revvity

A number of institutional investors and hedge funds have recently modified their holdings of RVTY. Public Employees Retirement System of Ohio acquired a new position in shares of Revvity in the 2nd quarter worth $3,845,000. The Manufacturers Life Insurance Company raised its position in shares of Revvity by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company’s stock worth $41,048,000 after purchasing an additional 20,278 shares during the period. Wellington Management Group LLP raised its position in shares of Revvity by 10,653.8% during the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock worth $96,304,000 after purchasing an additional 857,526 shares during the period. Tocqueville Asset Management L.P. purchased a new stake in shares of Revvity during the second quarter valued at $4,791,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Revvity during the second quarter valued at $78,766,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.